Literature DB >> 26107202

Endothelial Cell Proliferation and Vascular Endothelial Growth Factor Expression in Primary Colorectal Cancer and Corresponding Liver Metastases.

Balica Amalia Raluca1, Anca Maria Cimpean, Andreea Cioca, Octavian Cretu, Ovidiu Mederle, Alexandru Ciolofan, Pusa Gaje, Marius Raica.   

Abstract

BACKGROUND: . Colorectal carcinoma (CRC) is one of the major causes of cancer death worldwide. Data from the literature indicate differences between the proliferation rate of endothelial cells relative to the morphology growth type, possibly due to origin of specimens (autopsy material, surgery fragments) or quantification methods. Vascular endothelial growth factor (VEGF) is a factor that stimulates the proliferation of endothelial cells. It is expressed in more than 90% of cases of metastatic CRC. AIM: The aim of this study was to evaluate the endothelial cell proliferation and VEGF expression in primary tumors and corresponding liver metastases.
MATERIALS AND METHODS: Our study included 24 recent biopsies of primary tumors and corresponding liver metastases of CRC cases. CD34/ Ki67 double immunostaining and RNA scope assay for VEGF were performed.
RESULTS: In the primary tumors analysis of VEGFmRNA expression indicated no significant correlation with differentiation grade, proliferative and non-proliferative vessels in the intratumoral and peritumoral areas. In contrast, in the corresponding liver metastases, VEGFmRNA expression significantly correlated with the total number of non- proliferative vessels and total number of vessels. CD34/ Ki67 double immunostaining in the cases with poorly differentiated carcinoma indicated a high number of proliferating endothelial cells in the peritumoral area and a low number in the intratumoral area for the primary tumor. Moderately differentiated carcinomas of colon showed no proliferating endothelial cells in the intratumoral area in half of the cases included in the study, for both, primary tumor and liver metastasis. In well differentiated CRCs, in primary tumors, a high proliferation rate of endothelial cells in the intratumoral area and a lower proliferation rate in the peritumoral area were found. A low value was found in corresponding liver metastasis.
CONCLUSIONS: The absence of proliferative endothelial cells in half of the cases for the primary tumors and liver metastases in moderately differentiated carcinoma suggest a vascular mimicry phenomenon. The mismatch between the total number of vessels and endothelial proliferation in primary tumors indicate that a functional vascular network is already formed or the existence of some mechanisms influenced by other angiogenic factors.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26107202     DOI: 10.7314/apjcp.2015.16.11.4549

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  4 in total

1.  Clusterin induced by N,N'-Dinitrosopiperazine is involved in nasopharyngeal carcinoma metastasis.

Authors:  Yuejin Li; Jinping Lu; Shan Zhou; Weiwei Wang; Gongjun Tan; Zhenlin Zhang; Zigang Dong; Tiebang Kang; Faqing Tang
Journal:  Oncotarget       Date:  2016-02-02

2.  Effects of Copper Reduction on Angiogenesis-Related Factorszzm321990in Recurrent Glioblastoma Cases

Authors:  Shima Jazayeri; Alireza Feli; Mohammad Ali Bitaraf; Masoud Solaymani Dodaran; Mazdak Alikhani; Mohammad Javad Hosseinzadeh-Attar
Journal:  Asian Pac J Cancer Prev       Date:  2016-10-01

3.  Vascular Endothelial Growth Factor and Cluster of Differentiation 34 for Assessment of Perioperative Bleeding Risk in Gastric Cancer Patients.

Authors:  Mu-Qing He; Mu-Qun He; Jian-Feng Wang; Bao-Ling Zhu; Ni Sun; Xiao-Hai Zhou; Rong-Xin Yao
Journal:  Chin Med J (Engl)       Date:  2016-08-20       Impact factor: 2.628

4.  Angiogenesis in primary colorectal cancer and matched metastatic tissues: Biological and clinical implications for anti-angiogenic therapies.

Authors:  Lei Yin; Jianning Li; Dejian Ma; Donghua Li; Yanlai Sun
Journal:  Oncol Lett       Date:  2020-03-06       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.